Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 6/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL323153 | 0.99 | CNR2 (0.45) | CNR2RAF1BRAFMAPK14MEN1 | |
| SCHEMBL322788 | 0.89 | CNR2 (0.41) | CNR2RAF1BRAFMAPK14MEN1 | |
| SCHEMBL323395 | 0.88 | CNR2 (0.51) | CNR2MEN1KMT2ADRD3 | |
| Hydrochloric Acid SCHEMBL323512 | 0.88 | CNR2 (0.50) | CNR2MEN1KMT2ADRD3 | |
| SCHEMBL327062 | 0.86 | CNR2 (0.48) | CNR2MEN1KMT2ADRD3HRH3 | |
| SCHEMBL323516 | 0.85 | CNR2 (0.49) | CNR2MEN1KMT2ADRD3 | |
| Hydrochloric Acid SCHEMBL322795 | 0.85 | CNR2 (0.47) | CNR2MEN1KMT2ADRD3HRH3 | |
| SCHEMBL327076 | 0.85 | CNR2 (0.49) | CNR2MEN1KMT2ADRD3S1PR5 | |
| SCHEMBL323951 | 0.85 | CNR2 (0.47) | CNR2MEN1KMT2ADRD3S1PR1 | |
| Hydrochloric Acid SCHEMBL324780 | 0.84 | CNR2 (0.48) | CNR2MEN1KMT2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662337-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2017-05-30 | — | — | US | claimed |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2016-06-02 | — | — | US | claimed |
| EP-2590954-B1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BV (NL) | 2016-04-13 | — | — | EP | claimed |
| US-9029371-B2 | Bisaryl (thio)morpholine derivatives as S1P modulators | ABBVIE B.V. (NL) | 2015-05-12 | — | — | US | claimed |
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-08-08 | — | — | US | claimed |
| EP-2590954-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE B.V. (NL) | 2013-05-15 | — | — | EP | claimed |
| WO-2012004375-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2012-01-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203745-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | CNR2 9/4885RAF1 1144/4885BRAF 1186/4885 |
| US-20160151376-A1 | BISARYL (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR1, S1PR3, S1PR2 | CNR2 25/4885RAF1 971/4885BRAF 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.